Mettler-Toledo International (NYSE: MTD - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Volatility and Risk Mettler-Toledo International has a beta of

Mettler-Toledo International (NYSE: MTD - Get Free Report) and Personalis (NASDAQ: PSNL - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Profitability This table compares Mettler-Toledo International and Personalis' net

Bank of America Corp DE purchased a new position in shares of Mettler-Toledo International, Inc. (NYSE: MTD) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 188,505 shares of the medical instruments supplier's stock, valued at approximately $240,817,000. Bank of America

California State Teachers Retirement System grew its position in shares of Mettler-Toledo International, Inc. (NYSE: MTD) by 114,807.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,100,865 shares of the medical instruments supplier's stock after buying an additional 35,070,318 shares during

Bank of Nova Scotia purchased a new stake in Mettler-Toledo International, Inc. (NYSE: MTD) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 3,306 shares of the medical instruments supplier's stock, valued at approximately $4,223,000. A number of other hedge funds have also

Mettler-Toledo (MTD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The transaction involved the disposition of 417 shares valued at $601,000, based on a weighted-average execution price of $1,440.41 per share. Salice maintains a significant interest through indirect holdings in SRB Investments LLC and Teaghlach LLC.

This executive disposed of 240 shares for about $343,000 on August 3. The sale was executed immediately following the exercise of 240 options with an exercise price of $720.81 per share.

The transaction involved the sale of 415 shares at $1,444.62 per share, representing an estimated value of about $599,517 on August 3. The disposition resulted from the immediate sale of shares acquired through the exercise of 415 stock options at a strike price of $397.95.

The disposition involved 2,240 shares at $1,432 per share, totaling about $3.2 million on August 3, 2026. The transaction was structured as a same-day exercise-and-sell involving 2,240 stock options at an exercise price of $595.31.